Navigation Links
ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
Date:4/14/2008

HAIFA, Israel, April 14 /PRNewswire/ -- ES Vascular Ltd. announced today that it has received a CE Mark approval for its Open Aortic Stapler (OAS) system for mechanical suturing technology of aortic synthetic grafts during open repair of AAA and other aortic reconstructions, enabling commercialization of the device in most European countries. Based on its proprietary stapling technology, the OAS stapler is a unique device that enables one shot stapling of synthetic grafts to aorta in open repair of abdominal and thoracic aneurysmal and occlusive disease, replacing lengthy and cumbersome manual suturing in these major procedures.

"We are very pleased to have received CE Mark for our OAS device and will immediately implement our strategy to make it available in approved countries. Positive clinical data position OAS to be a break-through product for patients and physicians alike," said Shuki Porath, CEO of ES Vascular.

Prof. Ralf Kolvenbach, Chief of Vascular Surgery and Endovascular Therapy at Augusta Hospital in Dusseldorf, Germany and a principal investigator for the OAS clinical trial program, commented, "OAS provides the construction of a geometrically perfect, uniform and standardized anastomosis that will not depend on the skills of the surgeon, is one of the principles lying behind the design of the OAS. This safety and feasibility trial showed that we now have the technology to use aortic stapling in a clinical setting. The aortic stapler can create a uniform staple line between any synthetic vascular prosthesis and the aortic wall. It is a simple, safe, rapid and reliable technique to perform a sutureless, end-to-end anastomosis in patients with aortic aneurysms or occlusive disease."

ES Vascular will be presenting the OAS and other products at the MedtechInsight conference "Investment In Innovation (In3) Europe", Paris, April 29-30.

About OAS System

The OAS system is comprised of applier and implantable staples and also includes specially designed clamp. The OAS device consists of two parts: a barrel shaped head and a handle. The head of the OAS device is pre-loaded with 10 stainless steel (316 LVM) staples that can be fired in one shot from the inside of the aorta to the outside through the synthetic graft. The staples form a pseudo-continuous suturing line, firmly attaching the graft to the aorta. The OAS is available in 16, 18, 20 and 22 mm diameters.

About ES Vascular, Ltd.

ES Vascular Ltd., http://www.esvascular.com, a privately held company, is engaged in the development, licensing and commercialization of its proprietary product line of one-shot, instantaneous anastomotic stapling devices for open, laparoscopic and endovascular abdominal and thoracic aortic surgery and for minimally invasive surgery of SFA. Their use is anticipated to revolutionize vascular surgery resulting in improved clinical outcome, higher patient benefit and decreased costs.

ES Vascular will be presenting the OAS and other products at the MedtechInsight conference "Investment In Innovation (In3) Europe", Paris, April 29-30.

Contact:

Shuki Porath, CEO,

+972-544-336-486,

Shuki@esvacular.com.


'/>"/>
SOURCE ES Vascular Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
2. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
3. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
4. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
5. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
6. BioVascular, Inc. Expands Executive Team
7. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
8. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
11. The Wisconsin Heart Hospital Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):